What’s Next? Five Things To Look Out For In September

Another US Ustekinumab Approval Awaits; Generic Competition To Sprycel On The Horizon

Generics Bulletin previews the most noteworthy and anticipated events for September 2024.

What's Next Image
• Source: Norstella/Citeline

This month, the US Food and Drug Administration is set to issue its decision on Formycon’s FYB202 proposed biosimilar to Stelara (ustekinumab), teeing up a potential launch in April 2025.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products